FULGENT GENETICS, INC. Impairment of Intangible Assets, Finite-lived
FULGENT GENETICS, INC. (FLGT) reported Impairment of Intangible Assets, Finite-lived of $2.17 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-07-30
- 2026-06-30: Impairment of Intangible Assets, Finite-lived 6 month $2.17M.
- 2025-06-30: Impairment of Intangible Assets, Finite-lived 6 month $0.00.
| Period end | Impairment of Intangible Assets, Finite-lived 6 month |
|---|---|
| 2026-06-30 | $2.17M 10-Q · filed 2026-07-30 |
| 2025-06-30 | $0.00 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |